Basal-bolus Insulin Therapy Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.
Also called NCT03244241
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT03244241
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Denmark
- Registry status
- Unknown status
Technical summary
Registry record NCT03244241. Randomized; no masking; primary purpose treatment. Start 2017-04-01 (actual); primary completion 2018-04-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Basal-bolus Insulin Therapy Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Insulin Degludec 100 UNT/ML [Tresiba]
- Lead sponsor
- Merete Bechmann Christensen
- Collaborator
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct03244241- Content hash
01b215b209e2fd34db837cb64931c0ccca93457f07d6978fe9ebfb00fdfe3800